Vedolizumab for the treatment of ulcerative colitis and Crohn’s disease

943b Induction Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial

(2015) B.G. Feagan et al.   GASTROENTEROLOGY

Treatment of inflammatory bowel disease (IBD)

(2014) Anand B. Pithadia et al.   Pharmacological Reports

Hospitalisations and surgery in Crohn's disease

(2012) Charles N Bernstein et al.   GUT

Structural specializations of α4β7, an integrin that mediates rolling adhesion

(2012) Yamei Yu et al.   JOURNAL OF CELL BIOLOGY

Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab

(2011) B. G. Feagan et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review article: loss of response to anti-TNF treatments in Crohn’s disease

(2011) S. Ben-Horin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review article: remission rates achievable by current therapies for inflammatory bowel disease

(2011) L. Peyrin-Biroulet et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

(2011) Alexander C Ford et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Methotrexate: A Drug of the Future in Ulcerative Colitis?

(2011) Franck Carbonnel   CURRENT DRUG TARGETS

Emerging immunological targets in inflammatory bowel disease

(2011) Giovanni Monteleone et al.   CURRENT OPINION IN PHARMACOLOGY

Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

(2011) Natalie A. Molodecky et al.   GASTROENTEROLOGY

The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study

(2011) S. Vermeire et al.   GUT

Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study

(2011) Asit Parikh et al.   INFLAMMATORY BOWEL DISEASES

Antibody-based therapeutics to watch in 2011

(2011) Janice M. Reichert   mAbs

Bases moleculares de las interacciones leucocito-endotelio durante la respuesta inflamatoria

(2011) Olga Barreiro et al.   REVISTA ESPANOLA DE CARDIOLOGIA

Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease

(2011) Chadwick Williams et al.   Therapeutic Advances in Gastroenterology

Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis

(2011) Saskia Thomas et al.   INFLAMMOPHARMACOLOGY

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

(2010) Waqqas Afif et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists

(2010) Hilbert S. De Vries et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease

(2010) Gionata Fiorino et al.   Expert Review of Clinical Immunology

Leukocytoclastic vasculitis

(2010) Sami Karoui et al.   INFLAMMATORY BOWEL DISEASES

Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States

(2010) K. T. Park et al.   INFLAMMATORY BOWEL DISEASES

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of methotrexate in Crohn’s disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine

(2009) M. WAHED et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial

(2009) Jean-Frédéric Colombel et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Anti-Adhesion Molecule Strategies for Crohn Disease

(2009) Yvette Leung et al.   BIODRUGS

S1066 Oral Alpha-4 Integrin Inhibitor (AJM300) in Patients with Active Crohn's Disease — A Randomized, Double-Blind, Placebo-Controlled Trial

(2009) Masakazu Takazoe et al.   GASTROENTEROLOGY

Rare Neurological Condition Linked to Newer Monoclonal Antibody Biologics

(2009) Bridget M. Kuehn   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti- 4 7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases

(2009) D. Soler et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Adverse Events Associated With the Use of Cyclosporine in Patients With Inflammatory Bowel Disease

(2008) Michael B. Sternthal et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

(2008) R Fleischmann et al.   ANNALS OF THE RHEUMATIC DISEASES

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

(2008) T R D J Radstake et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin

(2008) Brian G. Feagan et al.   Clinical Gastroenterology and Hepatology

Extraintestinal manifestations of inflammatory bowel disease

(2008) S. Ardizzone et al.   DIGESTIVE AND LIVER DISEASE

Direct Health Care Costs of Crohn's Disease and Ulcerative Colitis in US Children and Adults

(2008) Michael D. Kappelman et al.   GASTROENTEROLOGY